GlassScriptPhysician profile
Kathryn Bachman
NPI 1124430459
$801.04
in general payments reported to CMS, 2019-2025
22 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.89 · 2022: $276 · 2023: $145 · 2024: $103 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $125.28 | 2025 | Korlym |
| Abbvie INC. | $99.38 | 2022-2023 | Vraylar |
| Pfizer INC. | $86.95 | 2022-2025 | |
| Dexcom, INC. | $51.78 | 2023-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $47.39 | 2022-2023 | |
| Ethicon INC. | $43.22 | 2025 | Monarch Platform |
| Abbott Laboratories | $39.12 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $38.90 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.32 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $28.19 | 2022-2024 | Airsupra |
| Supernus Pharmaceuticals, INC. | $25.37 | 2022 | |
| Amarin Pharma, INC. | $20.95 | 2022 | |
| Insulet Corporation | $20.34 | 2025 | Omnipod |
| Mayne Pharma Commercial LLC | $19.33 | 2023 | |
| Novo Nordisk INC | $18.87 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $17.29 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.20 | 2023 | Jardiance |
| Hologic Sales and Service, LLC | $14.78 | 2024 | Aptima |
| Amgen INC. | $13.83 | 2024 | Otezla, Repatha |
| Terumo Medical Corporation | $13.31 | 2024 | Azur Cx Detachable |
| Lilly USA, LLC | $12.66 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Bachman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.